{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T17:29:49Z","timestamp":1772040589958,"version":"3.50.1"},"reference-count":33,"publisher":"Bentham Science Publishers Ltd.","issue":"7","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["IDDT"],"published-print":{"date-parts":[[2022,11]]},"abstract":"<jats:sec>\n<jats:title>Abstract:<\/jats:title>\n<jats:p>More than 200 viruses infect humans, but treatments are available for less than ten of them.\nTo narrow the gap between \u2018bugs and drugs,\u2019 a paradigm shift is required. The \u201cone drug, one bug\u201d\napproach can be expanded to a \u201cone drug, multiple bugs\u201d strategy such that the host\u2019s defense system\nis targeted rather than the virus. Viral superinfection therapy (SIT) activates interferon genes\u2019 natural,\nantiviral defense system of host cells following exposure to viral infection, e.g., superinfection with an\nattenuated infectious bursal disease virus (IBDV) with the release of its double-stranded RNA (dsRNA)\ncargo inside host cells. An attenuated IBDV therapeutic vaccine has successfully treated hepatitis\nA virus infection (HAV) in marmoset monkeys as well as acute hepatitis B and hepatitis C virus infections\n(HBV\/HCV) in 42 patients. SIT has also been shown to be safe and effective in four patients with\nchronic HBV or HCV infection with hepatic decompensation. The proof-of-principle of SIT has also\nbeen demonstrated in a 43-year-old male patient with COVID-19. Three doses of orally administered\nIBDV (3x106 IU) alleviated most of his COVID-19 symptoms; even his sense of smell returned within\na week. Two additional COVID-19 patients responded similarly to oral treatment with IBDV. Furthermore,\na severe herpes zoster ophthalmicus outbreak with orbital edema responded to a combination\nof acyclovir and 7 doses of IBDV (7x106 IU) within a few days. IBDV is simple to manufacture and\naffordable, even in resource-limited settings. Acid-resistant IBDV can be orally administered in an\noutpatient setting, providing simple dosing and high medication adherence. Under an Emergency Use\nAuthorization, the broad-spectrum IBDV drug candidate could be tested immediately in clinical trials\nand rapidly distributed to millions of early-stage patients with COVID-19. The German Paul Ehrlich\nInstitute is currently supporting a phase I safety study for persons acutely infected with SARS\u2011CoV-2.\nAn expert team of the US National Institutes of Health-sponsored ACTIV public-private partnership\ncame to the conclusion that the IBDV drug candidate shows merit as a potential treatment for COVID-\n19, and an FDA-approved clinical trial is in the pipelines in Los Angeles.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1871526522666220419130403","type":"journal-article","created":{"date-parts":[[2022,4,20]],"date-time":"2022-04-20T07:42:22Z","timestamp":1650440542000},"update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["A Clinically Validated, Broadly Active, Oral Viral Superinfection\nTherapy Could Mitigate Symptoms in Early-stage COVID-19 Patients"],"prefix":"10.2174","volume":"22","author":[{"given":"Tibor","family":"Bakacs","sequence":"first","affiliation":[{"name":"HepC, Inc, 1012 Budapest, Miko str. 3. II. fl. 11., Hungary"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Volker","family":"Sandig","sequence":"additional","affiliation":[{"name":"ProBioGen AG, Standort HBS Herbert-Bayer-Stra\u00dfe 8,\n13086 Berlin, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shimon","family":"Slavin","sequence":"additional","affiliation":[{"name":"Biotherapy International, The Center for Innovative Cancer Immunotherapy &amp; Cellular\nMedicine, Tel Aviv, Israel, Weizmann Center, 14 Weizmann Street Floor 15, Suite 1503 Tel Aviv 64239, Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Serhat","family":"Gumrukcu","sequence":"additional","affiliation":[{"name":"Seraph\nResearch Institute, 2080 Century Park East, Suite 710, Los Angeles, CA 90067, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Hardy","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases,\nKeck School of Medicine of The University of Southern California (USC), California, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wolfgang","family":"Renz","sequence":"additional","affiliation":[{"name":"Division of General\nSurgery, McGill University, Montreal, Canada"},{"name":"Executive School of Management, Technology and Law, University of\nSankt Gallen, Sankt Gallen, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Imre","family":"Kovesdi","sequence":"additional","affiliation":[{"name":"DNAtrix Inc, 10355 Science Center Drive, Suite 110, San Diego, CA 92121,\nUSA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1126\/science.aap7463","volume":"359","author":"Carroll D.","year":"2018","unstructured":"Carroll D.; Daszak P.; Wolfe N.D.; The global virome pro-ject. Science 2018,359(6378),872-874","journal-title":"Science"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1126\/science.aaa3778","volume":"348","author":"Bekerman E.","year":"2015","unstructured":"Bekerman E.; Einav S.; Combating emerging viral threats. Science 2015,348(6232),282-283","journal-title":"Science"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"tpmd210606","DOI":"10.4269\/ajtmh.21-0606","author":"Abd-Elsalam S.","year":"2021","unstructured":"Abd-Elsalam S.; Ahmed O.A.; Mansour N.O.; Remdesivir efficacy\nin COVID-19 treatment: A randomized controlled trial. Am J Trop\nMed Hyg 2021,tpmd210606","journal-title":"Am J Trop\nMed Hyg"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"5833","DOI":"10.1002\/jmv.27122","volume":"93","author":"Abd-Elsalam S.","year":"2021","unstructured":"Abd-Elsalam S.; Noor R.A.; Badawi R.; Clinical study evalu-ating the efficacy of ivermectin in COVID-19 treatment: A ran-domized controlled study. J Med Virol 2021,93(10),5833-5838","journal-title":"J Med Virol"},{"key":"ref=5","first-page":"1","author":"El-Bendary M.","year":"2021","unstructured":"El-Bendary M.; Abd-Elsalam S.; Elbaz T.; Efficacy of com-bined Sofosbuvir and Daclatasvir in the treatment of COVID-19 patients with pneumonia: A multicenter Egyptian study. Expert Rev Anti Infect Ther 2021,1-5","journal-title":"Expert Rev Anti Infect Ther"},{"key":"ref=6","first-page":"2020.10.15.20209817","author":"Pan H.","year":"2020","unstructured":"Pan H.; Peto R.; Abdool Karim Q.; Repurposed antiviral drugs for COVID-19; interim WHO SOLIDARITY trial results. medRxiv 2020,2020.10.15.20209817","journal-title":"medRxiv"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1038\/d41586-021-03074-5","volume":"599","author":"Ledford H.","year":"2021","unstructured":"Ledford H.; COVID antiviral pills: What scientists still want to know. Nature 2021,599(7885),358-359","journal-title":"Nature"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1038\/nrd.2017.162","volume":"17","author":"Kaufmann S.H.E.","year":"2018","unstructured":"Kaufmann S.H.E.; Dorhoi A.; Hotchkiss R.S.; Bartenschlager R.; Host-directed therapies for bacterial and viral infections. Nat Rev Drug Discov 2018,17(1),35-56","journal-title":"Nat Rev Drug Discov"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1038\/s41591-021-01282-0","volume":"27","author":"Meganck R.M.","year":"2021","unstructured":"Meganck R.M.; Baric R.S.; Developing therapeutic approaches for twenty-first-century emerging infectious viral diseases. Nat Med 2021,27(3),401-410","journal-title":"Nat Med"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"116356","DOI":"10.1016\/j.bmc.2021.116356","volume":"46","author":"Mahajan S.","year":"2021","unstructured":"Mahajan S.; Choudhary S.; Kumar P.; Tomar S.; Antiviral strate-gies targeting host factors and mechanisms obliging +ssRNA vi-ral pathogens. Bioorg Med Chem 2021,46,116356","journal-title":"Bioorg Med Chem"},{"key":"ref=11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2174\/187152651901190204152326","volume":"19","author":"Kovesdi I.","year":"2019","unstructured":"Kovesdi I.; Bakacs T.; Therapeutic exploitation of viral interfer-ence. Infect Disord Drug Targets 2019,19,1-1","journal-title":"Infect Disord Drug Targets"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s41124-017-0028-x","volume":"3","author":"Bakacs T.","year":"2018","unstructured":"Bakacs T.; Safadi R.; Kovesdi I.; Post-infection viral superinfec-tion technology could treat HBV and HCV patients with unmet needs. Hepatol Med Policy 2018,3(1),2","journal-title":"Hepatol Med Policy"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1038\/35099560","volume":"413","author":"Alexopoulou L.","year":"2001","unstructured":"Alexopoulou L.; Holt A.C.; Medzhitov R.; Flavell R.A.; Recognition of double-stranded RNA and activation of NF-\u03baB by Toll-like receptor 3. Nature 2001,413(6857),732-738","journal-title":"Nature"},{"key":"ref=14","first-page":"153","volume":"31","author":"Csatary L.K.","year":"1984","unstructured":"Csatary L.K.; Kasza L.; Massey R.J.; Interference between human hepatitis A virus and an attenuated apathogenic avian virus. Acta Microbiol Hung 1984,31(2),153-158","journal-title":"Acta Microbiol Hung"},{"key":"ref=15","first-page":"1279","volume":"18","author":"Csatary L.K.","year":"1998","unstructured":"Csatary L.K.; Telegdy L.; Gergely P.; Bodey B.; Bak\u00e1cs T.; Prelimi-nary report of a controlled trial of MTH-68\/B virus vaccine treatment in acute B and C hepatitis: A phase II study. Anticancer Res 1998,18(2B),1279-1282","journal-title":"Anticancer Res"},{"key":"ref=16","first-page":"629","volume":"19","author":"Csatary L.K.","year":"1999","unstructured":"Csatary L.K.; Schnabel R.; Bak\u00e1cs T.; Successful treatment of decompensated chronic viral hepatitis by bursal disease virus vaccine. Anticancer Res 1999,19(1B),629-633","journal-title":"Anticancer Res"},{"key":"ref=17","first-page":"250","author":"Aul C.","year":"1997","unstructured":"Aul C.; Gattermann N.; Germing U.; Heyll A.;  Adverse effects of interferon treatment 1997,250-266","journal-title":"Adverse effects of interferon treatment"},{"key":"ref=18","first-page":"191","volume":"36","author":"Voroshilova M.K.","year":"1989","unstructured":"Voroshilova M.K.; Potential use of nonpathogenic enteroviruses for control of human disease. Prog Med Virol 1989,36,191-202","journal-title":"Prog Med Virol"},{"key":"ref=19","first-page":"37","author":"Chumakov M.P.","year":"1992","unstructured":"Chumakov M.P.; Voroshilova M.K.; Antsupova A.S.; Live enteroviral vaccines for the emergency nonspecific prevention of mass respiratory diseases during fall-winter epidemics of in-fluenza and acute respiratory diseases. Zh Mikrobiol Epidemiol Immunobiol 1992(11-12),37-40","journal-title":"Zh Mikrobiol Epidemiol Immunobiol"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1002\/jgm.2830","volume":"17","author":"Horny\u00e1k \u00c1.","year":"2015","unstructured":"Horny\u00e1k \u00c1.; Lipinski K.S.; Bakonyi T.; Effective multiple oral administration of reverse genetics engineered infectious bursal disease virus in mice in the presence of neutralizing anti-bodies. J Gene Med 2015,17(6-7),116-131","journal-title":"J Gene Med"},{"key":"ref=21","first-page":"2020.03.07.982264","author":"Lokugamage K.G.","year":"2020","unstructured":"Lokugamage K.G.; Schindewolf C.; Menachery V.D.; SARS-CoV-2 sensitive to type I interferon pretreatment. bioRxiv 2020,2020.03.07.982264","journal-title":"bioRxiv"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1126\/science.abc4262","volume":"368","author":"Chumakov K.","year":"2020","unstructured":"Chumakov K.; Benn C.S.; Aaby P.; Kottilil S.; Gallo R.; Can existing live vaccines prevent COVID-19? Science 2020,368(6496),1187-1188","journal-title":"Science"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"e2102775118","DOI":"10.1073\/pnas.2102775118","volume":"118","author":"Wang Y.","year":"2021","unstructured":"Wang Y.; Yang C.; Song Y.; Scalable live-attenuated SARS-CoV-2 vaccine candidate demonstrates preclinical safety and ef-ficacy. Proc Natl Acad Sci USA 2021,118(29),e2102775118","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1016\/j.vaccine.2008.11.066","volume":"27","author":"Jordan I.","year":"2009","unstructured":"Jordan I.; Vos A.; Beilfu\u00df S.; Neubert A.; Breul S.; Sandig V.; An avian cell line designed for production of highly attenuated vi-ruses. Vaccine 2009,27(5),748-756","journal-title":"Vaccine"},{"key":"ref=25","author":"Janniger C.K.","year":"2021","unstructured":"Janniger C.K.; Eastern J.S.; Hospenthal D.R.; Moon J.E.; Her-pes zoster treatment and management. Medscape J Med 2021","journal-title":"Medscape J Med"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"e20303","DOI":"10.7759\/cureus.20303","volume":"13","author":"Bakacs T.","year":"2021","unstructured":"Bakacs T.; Healing of severe herpes zoster ophthalmicus within a few days: An autobiographical case report. Cureus 2021,13(12),e20303","journal-title":"Cureus"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"2149","DOI":"10.1001\/jama.2020.22813","volume":"324","author":"Kim P.S.","year":"2020","unstructured":"Kim P.S.; Read S.W.; Fauci A.S.; Therapy for early COVID-19. JAMA 2020,324(21),2149-2150","journal-title":"JAMA"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.amjmed.2020.07.003","volume":"134","author":"McCullough P.A.","year":"2021","unstructured":"McCullough P.A.; Kelly R.J.; Ruocco G.; Pathophysiological basis and rationale for early outpatient treatment of SARS-CoV-2 (COVID-19) infection. Am J Med 2021,134(1),16-22","journal-title":"Am J Med"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1038\/s41591-021-01283-z","volume":"27","author":"Nalbandian A.","year":"2021","unstructured":"Nalbandian A.; Sehgal K.; Gupta A.; Post-acute COVID-19 syndrome. Nat Med 2021,27(4),601-615","journal-title":"Nat Med"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1001\/jama.2021.2828","volume":"325","author":"Murray C.J.L.","year":"2021","unstructured":"Murray C.J.L.; Piot P.; The potential future of the COVID-19 pan-demic. JAMA 2021,325(13),1249-1250","journal-title":"JAMA"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1126\/science.371.6527.329","volume":"371","author":"Kupferschmidt K.","year":"2021","unstructured":"Kupferschmidt K.; New mutations raise specter of \u2018immune escape\u2019. Science 2021,371(6527),329-330","journal-title":"Science"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1126\/science.abm3921","volume":"374","author":"Schoggins J.","year":"2021","unstructured":"Schoggins J.; Defective viral RNA sensing linked to severe COVID-19. Science 2021,374(6567),535-536","journal-title":"Science"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"eabj3624","DOI":"10.1126\/science.abj3624","volume":"374","author":"Wickenhagen A.","year":"2021","unstructured":"Wickenhagen A.; Sugrue E.; Lytras S.; ISARIC4C Investiga-tors. A prenylated dsRNA sensor protects against severe COVID-19. Science 2021,374(6567),eabj3624","journal-title":"Science"}],"container-title":["Infectious Disorders - Drug Targets"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1871526522666220419130403","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/203790\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1871526522666220419130403","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,27]],"date-time":"2023-08-27T18:18:00Z","timestamp":1693160280000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/203790\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":33,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1871526522666220419130403","relation":{},"ISSN":["1871-5265"],"issn-type":[{"value":"1871-5265","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2021-11-17","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-12-29","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-01-28","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-11-03","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e190422203790"}}